Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Janssen Biotech, Inc. (Details) $ in Thousands	1 Months Ended			3 Months Ended								12 Months Ended
	Dec. 31, 2016 USD ($)	Jul. 31, 2016 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2016 USD ($) Program	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue earned				$ 160,349	$ 110,927	$ 38,470	$ 36,874	$ 51,571	$ 49,121	$ 120,428	$ 62,583	$ 346,620	$ 283,703	$ 214,161
Janssen Biotech, Inc. [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Number of programs under which drugs are to be developed and commercialized | Program												3
Upfront payment recorded as deferred revenue			$ 35,000
Maximum amount of payments receivable for license fee and substantive milestones	$ 800,000			800,000								$ 800,000
Maximum amount of payments receivable for development milestones	175,000			175,000								175,000
Maximum amount of payments receivable for regulatory milestones	420,000			420,000								420,000
Maximum amount of payments receivable for commercialization milestones	180,000			180,000								180,000
Cumulative payments received	47,000			47,000								47,000
License fee received		$ 10,000
Revenue earned					$ 10,000							27,300	8,900	$ 0
Milestone payment earned	5,000
Next prospective milestone	5,000			5,000								5,000
Deferred revenue	$ 17,500			$ 17,500				$ 26,300				$ 17,500	$ 26,300